Neuren Pharmaceuticals Limited (ASX:NEU)

Neuren Pharmaceuticals Limited held its Annual General Meeting on May 27, 2026, highlighting significant financial and strategic growth. The company reported strong sales momentum for its drug DAYBUE, designed for neurodevelopmental disorders, with a substantial increase in income from its partnership with Acadia Pharmaceuticals. Financially robust, Neuren is well-positioned with $296 million in cash and short-term investments, enabling full funding of its research pipeline, including the promising NNZ-2591. The company is advancing NNZ-2591 through Phase 3 trials targeting Phelan-McDermid syndrome, with strategic plans to expand into other neurological disorders. This period of growth includes increased royalty income and expands upon its commercial success with DAYBUE. Neuren's leadership team remains focused on developing treatments for rare neurological conditions, aiming to enhance shareholder value while addressing unmet medical needs in neurodevelopmental disabilities.